Lithium carbonate
Lithium, Lithobid (lithium carbonate) is a small molecule pharmaceutical. Lithium carbonate was first approved as Lithobid on 1982-01-01. It is used to treat bipolar disorder, conduct disorder, depressive disorder, and post-traumatic stress disorders in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lithane | 2006-06-12 | |
| lithium | ANDA | 2024-12-11 |
| lithium carbonate | New Drug Application | 2025-03-10 |
| lithium carbonate extended release | 2007-03-30 | |
| lithium carbonate lithium carbonate | ANDA | 2022-11-24 |
| lithium lithium carbonate | New Drug Application | 2022-11-22 |
| lithobid | New Drug Application | 2022-10-28 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
425 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 2 | — | — | 2 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lithium carbonate |
| INN | — |
| Description | Lithium carbonate is a lithium salt and a carbonate salt. It has a role as an antimanic drug. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C([O-])[O-].[Li+].[Li+] |
Identifiers
| PDB | — |
| CAS-ID | 554-13-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200826 |
| ChEBI ID | 6504 |
| PubChem CID | 11125 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 61,290 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lithane, Lithium, Lithium carbonate, Lithium carbonate lithium carbonate, Lithium lithium carbonate, Lithobid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,159 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use